Ligand id: 8423

Name: pimavanserin

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 10
Topological polar surface area 44.81
Molecular weight 427.26
XLogP 5.03
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
In 2014 US FDA granted breakthrough therapy status for pimavanserin as a potential treatment for Parkinson's disease psychosis, following the completion of Phase III clinical trials for this indication. A Phase II trial administering pimavanserin as an adjunctive treatment for schizophrenia (in combination with antipsychotic medications such as risperidone and haloperidol) has also been completed. A further Phase II trial in patients with Alzheimer's disease psychosis is underway.
In November 2015, the US FDA confirmed that the New Drug Application (NDA) for Nuplazid® branded pimavanserin will be considered under it's 'Priority Review' process, to expedite its approval as a treatment of psychosis associated with Parkinson's disease, a condition for which there was no previous FDA-approved therapy. This Priority Review resulted in a 2016 approval for treating hallucinations and delusions associated with Parkinson's disease.